国际中医中药杂志
國際中醫中藥雜誌
국제중의중약잡지
INTERNATIONAL JOURNAL OF TRIDITIONAL CHINESE MEDICINE
2012年
2期
106-108
,共3页
王晓瞳%李杰%刘瑞%张玉人
王曉瞳%李傑%劉瑞%張玉人
왕효동%리걸%류서%장옥인
肿瘤标志物%疾病进展时间%一年生存期
腫瘤標誌物%疾病進展時間%一年生存期
종류표지물%질병진전시간%일년생존기
Tumor markers%Time to progression%One year survival
目的 探讨非小细胞肺癌血清肿瘤标志物(tumor marker,TM)与疾病远期疗效的关系.方法 对中国中医科学院广安门医院肿瘤科于2006年10月至2009年3月收治的178例非小细胞肺癌患者的血清肿瘤标志物水平,按疾病进展时间(time to progression,TTP)分为5组,组1(0～3个月)70例、组2(4～6个月)40例、组3(7～9个月)25例、组4(10～12个月)25例、组5(＞12个月)18例,分析TTP与一年生存的相关性.结果 TTP 1～5组的CA125含量分别为:(227.9±73.3)U/ml、(83.4±127.6)U/ml、(74.8±174.5)U/ml、(53.15±26.3)U/ml、(24.69±8.78)U/ml,差异有统计学意义(P=0.02),表明Ca125含量越高病程越快.TTP 1～5组的Cyfra211[分别为(9.8±9.4) ng/ml、(10±6.9) ng/ml、(41.55±9.3) ng/ml、(11.98±9.9) ng/ml、(4.1±0.5) ng/ml],CEA[分别为(88.4±227.0) ng/ml、(75.8±272.0) ng/ml、(33.1±30.6) ng/ml、(35.4±52.5) ng/ml、(17.1±15.4) ng/ml],Ca153[分别为(42.6±52.3) ng/ml、(47.6±147.0) ng/ml、(57.4±153) ng/ml、(19.4±12.7) ng/ml、(33.7±14.6) ng/ml]越高,一年生存的可能性越低(P=0.041).结论 非小细胞肺癌患者血清Ca125、Cyfra211、CEA、Ca153等水平对判断预后有一定的价值,合理选择肿瘤标志物进行检测对判断预后有参考价值.
目的 探討非小細胞肺癌血清腫瘤標誌物(tumor marker,TM)與疾病遠期療效的關繫.方法 對中國中醫科學院廣安門醫院腫瘤科于2006年10月至2009年3月收治的178例非小細胞肺癌患者的血清腫瘤標誌物水平,按疾病進展時間(time to progression,TTP)分為5組,組1(0～3箇月)70例、組2(4～6箇月)40例、組3(7～9箇月)25例、組4(10～12箇月)25例、組5(＞12箇月)18例,分析TTP與一年生存的相關性.結果 TTP 1～5組的CA125含量分彆為:(227.9±73.3)U/ml、(83.4±127.6)U/ml、(74.8±174.5)U/ml、(53.15±26.3)U/ml、(24.69±8.78)U/ml,差異有統計學意義(P=0.02),錶明Ca125含量越高病程越快.TTP 1～5組的Cyfra211[分彆為(9.8±9.4) ng/ml、(10±6.9) ng/ml、(41.55±9.3) ng/ml、(11.98±9.9) ng/ml、(4.1±0.5) ng/ml],CEA[分彆為(88.4±227.0) ng/ml、(75.8±272.0) ng/ml、(33.1±30.6) ng/ml、(35.4±52.5) ng/ml、(17.1±15.4) ng/ml],Ca153[分彆為(42.6±52.3) ng/ml、(47.6±147.0) ng/ml、(57.4±153) ng/ml、(19.4±12.7) ng/ml、(33.7±14.6) ng/ml]越高,一年生存的可能性越低(P=0.041).結論 非小細胞肺癌患者血清Ca125、Cyfra211、CEA、Ca153等水平對判斷預後有一定的價值,閤理選擇腫瘤標誌物進行檢測對判斷預後有參攷價值.
목적 탐토비소세포폐암혈청종류표지물(tumor marker,TM)여질병원기료효적관계.방법 대중국중의과학원엄안문의원종류과우2006년10월지2009년3월수치적178례비소세포폐암환자적혈청종류표지물수평,안질병진전시간(time to progression,TTP)분위5조,조1(0～3개월)70례、조2(4～6개월)40례、조3(7～9개월)25례、조4(10～12개월)25례、조5(＞12개월)18례,분석TTP여일년생존적상관성.결과 TTP 1～5조적CA125함량분별위:(227.9±73.3)U/ml、(83.4±127.6)U/ml、(74.8±174.5)U/ml、(53.15±26.3)U/ml、(24.69±8.78)U/ml,차이유통계학의의(P=0.02),표명Ca125함량월고병정월쾌.TTP 1～5조적Cyfra211[분별위(9.8±9.4) ng/ml、(10±6.9) ng/ml、(41.55±9.3) ng/ml、(11.98±9.9) ng/ml、(4.1±0.5) ng/ml],CEA[분별위(88.4±227.0) ng/ml、(75.8±272.0) ng/ml、(33.1±30.6) ng/ml、(35.4±52.5) ng/ml、(17.1±15.4) ng/ml],Ca153[분별위(42.6±52.3) ng/ml、(47.6±147.0) ng/ml、(57.4±153) ng/ml、(19.4±12.7) ng/ml、(33.7±14.6) ng/ml]월고,일년생존적가능성월저(P=0.041).결론 비소세포폐암환자혈청Ca125、Cyfra211、CEA、Ca153등수평대판단예후유일정적개치,합리선택종류표지물진행검측대판단예후유삼고개치.
Objective To detect the relationship between tumor markers (TM) and prognosis of NSCLC.Methods The level of TM of 178 NSCLC cases,which all accord with the standard of advanced NSCLC come from Guang'an Men Hospital of China Academy of TCM from 2006 October to 2009 March.Was divided into 5 groups:group 1 (0～3 months)、group 2 (4～6 months)、group 3 (7～9 months)、group 4 ( 10～ 12 months)、group 5 ( ＞ 12 months) according to time to progression (TTP).Studied the correlation between TM,TTP and one year survival retrospectively.Results The serum level of Ca125 in TTP 1～5 group was:(227.9± 73.3)U/ml,(83.4± 127.6)U/ml,(74.8 ± 174.5)U/ml,(53.15 ± 26.3)U/ml,(24.69± 8.78)U/ml respectively which indicated that the higher the serum level of Ca125 was,the more quickly the progress of disease would be(P=0.02); The serum level of Cyfra211 [(9.8±9.4)ng/ml,(10± 6.9) ng/ml,(41.55±9.3) ng/ml,(11.98 ± 9.9) ng/ml,(4.1 ± 0.5) ng/ml) ],CEA [ (88.4± 227) ng/ml,(75.8 ± 272) ng/ml,(57.4 ±153)ng/ml,(35.4±52.5)ng/ml,(17.1± 15.4)ng/ml] and Ca153 [(42.6±52.3)ng/ml,(47.6±147.0) ng/ml,(57.4± 153)ng/ml,(19.4± 12.7)ng/ml,(33.7± 14.6)ng/ml] was associated with prognosis,the higher level they were the lower possibility of one-year survival would be (P=0.041 ).Conclusion Ca 125、Cyfra211、CEA and Ca153 had certain value for prognostic judgment and it was of great significance that measuring rational serum tumor markers on judging prognosis of NSCLC.
